Skip to main content
. 2011 Jul;49(7):2711–2713. doi: 10.1128/JCM.00864-11

Fig. 1.

Fig. 1.

Distribution of cefepime MICs in Enterobacter blood culture isolates. *, 0% of the ESBL positive isolates and 86% of the ESBL negative isolates were susceptible to cefepime using the EUCAST breakpoint. **, 8% of the ESBL positive isolates and 94% of the ESBL negative isolates were susceptible to cefepime using the CLSI breakpoint. S/I, susceptible/intermediate.